Exagen Inc. (XGN)
XGN Stock Price Chart
Explore Exagen Inc. interactive price chart. Choose custom timeframes to analyze XGN price movements and trends.
XGN Company Profile
Discover essential business fundamentals and corporate details for Exagen Inc. (XGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
19 Sept 2019
Employees
209.00
Website
https://www.exagen.comCEO
John Aballi
Description
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
XGN Financial Timeline
Browse a chronological timeline of Exagen Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.19, while revenue estimate is $17.80m.
Earnings released on 11 May 2026
EPS came in at -$0.17 surpassing the estimated -$0.24 by +29.17%, while revenue for the quarter reached $17.31m , beating expectations by +5.47%.
Earnings released on 10 Mar 2026
EPS came in at -$0.20 matching the estimated -$0.20, while revenue for the quarter reached $16.63m , beating expectations by +0.37%.
Earnings released on 4 Nov 2025
EPS came in at -$0.19 falling short of the estimated -$0.13 by -46.15%, while revenue for the quarter reached $17.24m , beating expectations by +4.28%.
Earnings released on 29 Jul 2025
EPS came in at -$0.18 matching the estimated -$0.18, while revenue for the quarter reached $17.20m , beating expectations by +1.78%.
Earnings released on 5 May 2025
EPS came in at -$0.20 matching the estimated -$0.20, while revenue for the quarter reached $15.50m , beating expectations by +6.49%.
Earnings released on 11 Mar 2025
EPS came in at -$0.20 surpassing the estimated -$0.27 by +25.93%, while revenue for the quarter reached $13.66m , missing expectations by -6.26%.
Earnings released on 12 Nov 2024
EPS came in at -$0.28 surpassing the estimated -$0.30 by +6.67%, while revenue for the quarter reached $12.51m , missing expectations by -7.58%.
Earnings released on 5 Aug 2024
EPS came in at -$0.16 surpassing the estimated -$0.36 by +55.56%, while revenue for the quarter reached $15.06m , beating expectations by +11.01%.
Earnings released on 13 May 2024
EPS came in at -$0.19 surpassing the estimated -$0.40 by +52.50%, while revenue for the quarter reached $14.42m , beating expectations by +10.12%.
Earnings released on 18 Mar 2024
EPS came in at -$0.31 surpassing the estimated -$0.41 by +24.39%, while revenue for the quarter reached $13.77m , beating expectations by +19.07%.
Earnings released on 13 Nov 2023
EPS came in at -$0.31 surpassing the estimated -$0.50 by +38.00%, while revenue for the quarter reached $13.42m , beating expectations by +14.86%.
Earnings released on 7 Aug 2023
EPS came in at -$0.28 surpassing the estimated -$0.48 by +41.67%, while revenue for the quarter reached $14.14m , beating expectations by +33.62%.
Earnings released on 15 May 2023
EPS came in at -$0.44 surpassing the estimated -$0.52 by +15.38%, while revenue for the quarter reached $11.23m , beating expectations by +19.47%.
Earnings released on 20 Mar 2023
EPS came in at -$0.58 surpassing the estimated -$0.71 by +18.31%, while revenue for the quarter reached $12.84m , beating expectations by +48.23%.
Earnings released on 14 Nov 2022
EPS came in at -$0.47 surpassing the estimated -$0.76 by +38.16%, while revenue for the quarter reached $14.73m , beating expectations by +62.81%.
Earnings released on 4 Aug 2022
EPS came in at -$0.78 falling short of the estimated -$0.55 by -41.82%, while revenue for the quarter reached $8.96m , missing expectations by -25.50%.
Earnings released on 11 May 2022
EPS came in at -$0.60 falling short of the estimated -$0.59 by -1.69%, while revenue for the quarter reached $10.39m , beating expectations by +3.94%.
Earnings released on 22 Mar 2022
EPS came in at -$0.42 surpassing the estimated -$0.49 by +14.29%, while revenue for the quarter reached $12.69m , beating expectations by +8.37%.
Earnings released on 10 Nov 2021
EPS came in at -$0.42 surpassing the estimated -$0.43 by +2.33%, while revenue for the quarter reached $12.25m , missing expectations by -2.27%.
Earnings released on 9 Aug 2021
EPS came in at -$0.38 surpassing the estimated -$0.50 by +24.00%, while revenue for the quarter reached $12.77m , meeting expectations.
XGN Stock Performance
Access detailed XGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
